Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX15 | P16050 | 12/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.45 |
| ▸ | TSHR | P16473 | 2/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.43 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9124136 | 0.75 | KDM4E (0.58) | ALDH1A1TSHRKDM4EMEN1KMT2A | |
| SCHEMBL27027505 | 0.74 | GPR17 (0.53) | ALOX15ALDH1A1KDM4EMEN1KMT2A | |
| SCHEMBL31081306 | 0.74 | ALDH1A1 (0.53) | ALDH1A1TSHRKDM4ENPC1RAB9A | |
| SCHEMBL31081099 | 0.74 | ALDH1A1 (0.53) | ALDH1A1TSHRKDM4ENPC1RAB9A | |
| SCHEMBL9863260 | 0.74 | KDM4E (0.59) | ALDH1A1TSHRKDM4ERAB9A | |
| SCHEMBL31081184 | 0.74 | ALDH1A1 (0.53) | ALDH1A1TSHRKDM4ENPC1RAB9A | |
| SCHEMBL8794611 | 0.74 | ALDH1A1 (0.66) | ALOX15ALDH1A1KDM4EMEN1KMT2A | |
| SCHEMBL31080841 | 0.72 | TSHR (0.55) | ALDH1A1TSHRKDM4ENPC1RAB9A | |
| SCHEMBL8795754 | 0.72 | ALOX15 (0.61) | ALOX15 | |
| SCHEMBL8793660 | 0.72 | ALOX15 (0.85) | ALOX15ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10322999-B2 | Oxindoles derivatives, preparation method thereof and pharmaceutical compositions for the prevention or treatment of cancer containing the same as an active ingredient | Research & Business Foundation Sungkyunkwan University (KR) | 2019-06-18 | — | — | US | disclosed |
| US-10322999-B2 | Oxindoles derivatives, preparation method thereof and pharmaceutical compositions for the prevention or treatment of cancer containing the same as an active ingredient | Research & Business Foundation Sungkyunkwan University (KR) | 2019-06-18 | — | — | US | disclosed |
| US-20180339965-A1 | OXINDOLES DERIVATIVES, PREPARATION METHOD THEREOF AND PHARMACEUTICAL COMPOSITIONS FOR THE PREVENTION OR TREATMENT OF CANCER CONTAINING THE SAME AS AN ACTIVE INGREDIENT | Research & Business Foundation Sungkyunkwan University (KR) | 2018-11-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180339965-A1 | OXINDOLES DERIVATIVES, PREPARATION METHOD THEREOF AND PHARMACEUTICAL COMPOSITIONS FOR THE PREVENTION OR TREATMENT OF CANCER CONTAINING THE SAME AS AN ACTIVE INGREDIENT | ODC1, CCNI, CYP3A5 | ALOX15 783/4885ALDH1A1 884/4885TSHR 2884/4885 |
| US-10322999-B2 | Oxindoles derivatives, preparation method thereof and pharmaceutical compositions for the prevention or treatment of cancer containing the same as an active ingredient | ODC1, CCNI, CYP3A5 | ALOX15 783/4885ALDH1A1 884/4885TSHR 2884/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.